Drugs / VX-264
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05791201 | May 2023 → Mar 2027 expected | type 1 diabetes mellitus | Vertex Pharmaceuticals Incorporated | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-03-28 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces Program Updates for Type 1 Diabetes Portfolio vrtx.com ↗
VX-264 was generally safe and well tolerated; however, the study did not meet the efficacy endpoint. |
| 2023-03-09 | Vertex Pharmaceuticals Incorporated | Regulatory Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes vrtx.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-28 | Vertex Pharmaceuticals Incorporated | Vertex Announces Program Updates for Type 1 Diabetes Portfolio vrtx.com ↗ |
| 2023-03-09 | Vertex Pharmaceuticals Incorporated | Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes vrtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-264 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05791201 ↗ |
| Modality | Cell therapy | “Allogeneic human stem cell-derived islets.” NCT05791201 ↗ |